Prime Video has unveiled the trailer for The Traitors Telugu, a 10-episode reality series hosted by Teja Sajja. Featuring 20 celebrities, the show centres on hidden identities, shifting alliances and the challenge of deciding whom to trust.
The Traitors Telugu trailer sets up a tense competition
Trust takes centre stage in Prime Video’s upcoming reality series The Traitors Telugu, where 20 celebrities must identify the traitors concealed within their group. T
Prime Video has unveiled the trailer for The Traitors Telugu, a 10-episode reality series hosted by Teja Sajja. Featuring 20 celebrities, the show centres on hidden identities, shifting alliances and the challenge of deciding whom to trust.
The Traitors Telugu trailer sets up a tense competition
Trust takes centre stage in Prime Video’s upcoming reality series The Traitors Telugu, where 20 celebrities must identify the traitors concealed within their group. T
Supreme Court Seeks Records Before Intervention
The Supreme Court on Monday declined to pass an interim order suspending Chief Election Commissioner Gyanesh Kumar over allegations of unilateral decision-making within the Election Commission of India. Instead, it sought responses and records to examine how the disputed decisions were approved.
The petition challenges
Supreme Court Seeks Records Before Intervention
The Supreme Court on Monday declined to pass an interim order suspending Chief Election Commissioner Gyanesh Kumar over allegations of unilateral decision-making within the Election Commission of India. Instead, it sought responses and records to examine how the disputed decisions were approved.
The petition challenges
CJP Raises Arrest Concerns Ahead of Protest
Cockroach Janta Party (CJP) leader Abhijeet Dipke and other members could face arrest ahead of the organisation’s planned October 10 mobilisation, according to a claim made by spokesperson Saurav Das. The allegation comes amid protests demanding the resignation of Chief Election Commissioner Gyanesh Ku
CJP Raises Arrest Concerns Ahead of Protest
Cockroach Janta Party (CJP) leader Abhijeet Dipke and other members could face arrest ahead of the organisation’s planned October 10 mobilisation, according to a claim made by spokesperson Saurav Das. The allegation comes amid protests demanding the resignation of Chief Election Commissioner Gyanesh Ku
Sonia Gandhi and senior Congress leader Digvijaya Singh reportedly expressed differing views over Nitish Kumar’s departure from the INDIA bloc during a Congress Working Committee meeting. Which cited Congress sources, Singh argued that the Opposition should have made greater efforts to retain the JDU leader, while Gandhi rejected that assessment.
The reported exchange came during discussions on the Congress’s political strategy and its confrontation with th
Sonia Gandhi and senior Congress leader Digvijaya Singh reportedly expressed differing views over Nitish Kumar’s departure from the INDIA bloc during a Congress Working Committee meeting. Which cited Congress sources, Singh argued that the Opposition should have made greater efforts to retain the JDU leader, while Gandhi rejected that assessment.
The reported exchange came during discussions on the Congress’s political strategy and its confrontation with th
Samajwadi Party president Akhilesh Yadav’s decision to skip the INDIA bloc meeting in Delhi on Wednesday, September 30, has renewed questions about relations between the SP and Congress ahead of the Uttar Pradesh Assembly elections.
The Opposition gathering was called to discuss a joint agitation over alleged irregularities in the Special Intensive Revision of electoral rolls and to press for Chief Election Commissioner
Samajwadi Party president Akhilesh Yadav’s decision to skip the INDIA bloc meeting in Delhi on Wednesday, September 30, has renewed questions about relations between the SP and Congress ahead of the Uttar Pradesh Assembly elections.
The Opposition gathering was called to discuss a joint agitation over alleged irregularities in the Special Intensive Revision of electoral rolls and to press for Chief Election Commissioner
Sneha Reddy has built a public identity that brings together entrepreneurship, motherhood, fitness and lifestyle. Known as Allu Arjun’s wife, she also connects with a social-media community of more than 9.1 million followers.
Sneha Reddy’s Entrepreneurial Journey
Sneha Reddy’s professional life is an important part of her story. At the centre of her entrepreneurial journey is Picaboo, the studio she runs alongside her other commitments. Her involvement in
Sneha Reddy has built a public identity that brings together entrepreneurship, motherhood, fitness and lifestyle. Known as Allu Arjun’s wife, she also connects with a social-media community of more than 9.1 million followers.
Sneha Reddy’s Entrepreneurial Journey
Sneha Reddy’s professional life is an important part of her story. At the centre of her entrepreneurial journey is Picaboo, the studio she runs alongside her other commitments. Her involvement in
Andhra Pradesh has put emergency services on high alert as heavy rain, strong winds and the risk of flash floods affect parts of the state. The weather is linked to a deep depression, and the India Meteorological Department has warned of extremely heavy rain, thunderstorms and strong winds in coastal Andhra Pradesh on Thursday, September 24.
In Chinthalapadu village of Tiruvuru mandal in NTR district, powerful winds damaged houses and blew metal roofing sheets
Andhra Pradesh has put emergency services on high alert as heavy rain, strong winds and the risk of flash floods affect parts of the state. The weather is linked to a deep depression, and the India Meteorological Department has warned of extremely heavy rain, thunderstorms and strong winds in coastal Andhra Pradesh on Thursday, September 24.
In Chinthalapadu village of Tiruvuru mandal in NTR district, powerful winds damaged houses and blew metal roofing sheets
India has warned its nationals against using Malaysia’s 30-day visa-free entry facility to seek jobs, stressing that the arrangement is limited to tourism and social visits and does not permit any form of employment. The High Commission of India in Kuala Lumpur issued the advisory after observing a noticeable increase in Indians entering Malaysia under the visa-free scheme while intending to look for work.
Accordin
India has warned its nationals against using Malaysia’s 30-day visa-free entry facility to seek jobs, stressing that the arrangement is limited to tourism and social visits and does not permit any form of employment. The High Commission of India in Kuala Lumpur issued the advisory after observing a noticeable increase in Indians entering Malaysia under the visa-free scheme while intending to look for work.
Accordin
Oman’s Sohar Port is gaining attention as a potential alternative gateway for Indian companies seeking safer and more flexible access to Gulf markets amid disruptions around the Strait of Hormuz.
Located on the Gulf of Oman coast and beyond the narrowest section of the Hormuz chokepoint, Sohar offers connections through sea routes, highways and a planned rail link with the United Arab Emirates. Its location does not eli
Oman’s Sohar Port is gaining attention as a potential alternative gateway for Indian companies seeking safer and more flexible access to Gulf markets amid disruptions around the Strait of Hormuz.
Located on the Gulf of Oman coast and beyond the narrowest section of the Hormuz chokepoint, Sohar offers connections through sea routes, highways and a planned rail link with the United Arab Emirates. Its location does not eli
The long wait for Lord Venkateswara’s darshan at Tirumala is set to become more spiritually engaging as the Tirumala Tirupati Devasthanams introduces artificial intelligence, virtual reality and immersive visual storytelling at the Vaikuntam Queue Complex.
Chief Minister N. Chandrababu Naidu inaugurated the Rs 4 crore Devotional Experience Centre at Vaikuntam Queue Complex 1 on Wednesday. The facility has been launched on a pilot basis to engage devotees duri
The long wait for Lord Venkateswara’s darshan at Tirumala is set to become more spiritually engaging as the Tirumala Tirupati Devasthanams introduces artificial intelligence, virtual reality and immersive visual storytelling at the Vaikuntam Queue Complex.
Chief Minister N. Chandrababu Naidu inaugurated the Rs 4 crore Devotional Experience Centre at Vaikuntam Queue Complex 1 on Wednesday. The facility has been launched on a pilot basis to engage devotees duri
Washington, DC | Trump welcomed India’s action against illicit opium cultivation while the country remained on the US drug transit and production list.
US President Donald Trump has praised Prime Minister Narendra Modi and the Indian government for taking steps against illicit opium poppy cultivation and strengthening the integrity of pharmaceutical and narcotics-related supply chains.
Washington, DC | Trump welcomed India’s action against illicit opium cultivation while the country remained on the US drug transit and production list.
US President Donald Trump has praised Prime Minister Narendra Modi and the Indian government for taking steps against illicit opium poppy cultivation and strengthening the integrity of pharmaceutical and narcotics-related supply chains.
Chief Minister C Joseph Vijay returned from London with Rs 15,300 crore in investment commitments and plans to advance Tamil Nadu’s Motor Sports City.
Tamil Nadu Chief Minister C Joseph Vijay returned to Chennai on Thursday after completing a six-day official visit to London focused on attracting overseas investment, strengthening trade partnerships and accelerating industrial development in the state.
According to an off
Chief Minister C Joseph Vijay returned from London with Rs 15,300 crore in investment commitments and plans to advance Tamil Nadu’s Motor Sports City.
Tamil Nadu Chief Minister C Joseph Vijay returned to Chennai on Thursday after completing a six-day official visit to London focused on attracting overseas investment, strengthening trade partnerships and accelerating industrial development in the state.
According to an off
Health Ministry issues stem cell therapy advisory
The Union Ministry of Health and Family Welfare has issued an advisory directing all states and Union Territories to strictly enforce the rules governing stem cell research and therapy. The advisory, dated September 16, 2026, asks healthcare establishments, medical professionals and regulatory authorities to prevent unapproved stem cell interventions from being offered as established treatments.
The Ministry has clarified that stem cell therapy can be used as routine clinical care only for diseases and indications included in its approved list. Any treatment outside those approved uses must be regarded as experimental and cannot be promoted as a standard or commercially proven medical service.
Key points:
Only stem cell therapies approved by the Health Ministry may be offered as routine clinical care.
Experimental stem cell interventions cannot be advertised or promoted as proven cures.
Hospitals, clinics and doctors must comply with the applicable research and treatment regulations.
State and district authorities have been directed to monitor clinical establishments and investigate reported violations.
Stem cell therapy for autism remains experimental
The advisory specifically addresses claims that stem cell therapy can treat Autism Spectrum Disorder. The government has made it clear that the therapeutic use of any type of stem cell for autism is not approved as routine or standard clinical treatment.
Stem cell interventions involving autism may be undertaken only as part of duly approved clinical trials. These studies must follow the National Guidelines for Stem Cell Research, 2017, jointly issued by the Indian Council of Medical Research and the Department of Biotechnology.
Important conditions include:
Stem cell therapy for autism must remain restricted to authorised clinical trials.
The clinical trial must receive all necessary regulatory and ethics approvals.
Clinics cannot market experimental autism interventions as routine medical services.
Doctors cannot claim that stem cells are an established cure for autism.
Parents and caregivers should confirm a trial’s official registration and approvals before considering participation.
The advisory does not prohibit legitimate research but requires it to be conducted under approved clinical-trial safeguards.
NMC warns doctors against unauthorised practices
The National Medical Commission has reinforced the regulatory position through its advisory dated September 5, 2026. It has warned registered medical practitioners against administering, prescribing, recommending, promoting or advertising stem cell therapies for unapproved indications.
The NMC has stated that involvement in unauthorised stem cell treatment could amount to professional misconduct. State Medical Councils have been advised to examine complaints and initiate disciplinary proceedings when violations are established after due process.
The NMC directions cover the following actions:
Administering stem cell therapy for an indication that has not been approved.
Prescribing an experimental intervention as standard treatment.
Promoting unproven therapies through websites, social media or advertisements.
Making unsupported claims about guaranteed recovery or a permanent cure.
Commercially offering stem cell therapy outside an authorised clinical trial.
Failing to properly explain the experimental status and potential risks to patients.
Supreme Court judgment prompted stronger enforcement
The Health Ministry’s advisory follows the Supreme Court’s January 30, 2026 judgment in Yash Charitable Trust and Others versus Union of India and Others. The ruling emphasised that failure to comply with the statutory framework governing stem cell therapy must result in appropriate consequences.
The advisory reminds authorities that the existence of scientific research into stem cells does not permit clinics to sell unapproved interventions. Every therapeutic use must comply with the approved framework, and experimental research must remain within regulated clinical trials.
The judgment and subsequent advisory underline that:
Unapproved stem cell interventions cannot be treated as ordinary medical services.
Regulatory violations must result in meaningful action.
Medical professionals can be investigated for professional misconduct.
Clinical establishments may face penalties or loss of registration.
State authorities are responsible for enforcing the rules at the local level.
Penalties for violating stem cell therapy rules
Doctors found responsible for unauthorised stem cell therapy may face professional-misconduct proceedings under Regulation 7.22 of the Indian Medical Council Regulations, 2002. Any disciplinary action must be taken after examining the evidence and following the required legal process.
Clinical establishments may separately face action under Sections 32 and 40 of the Clinical Establishments Registration and Regulation Act, 2010. Depending on the nature of the violation, this can include financial penalties and cancellation of registration.
Possible consequences include:
Professional-misconduct proceedings against registered medical practitioners.
Disciplinary action by State Medical Councils.
Investigation of hospitals and clinics offering unauthorised treatments.
Penalties under the Clinical Establishments Act.
Cancellation of a clinical establishment’s registration in applicable cases.
Action against misleading promotion or advertisement of unproven therapies.
What patients and families should verify
Patients should not assume that every treatment described as “stem cell therapy” is approved, safe or clinically effective. Before agreeing to any such intervention, they should consult a qualified specialist and verify whether the proposed treatment is authorised for their medical condition.
Patients and families should check:
Whether the proposed stem cell treatment is approved for the diagnosed condition.
Whether it is being offered as standard treatment or as part of a clinical trial.
Whether the clinical trial has valid regulatory and ethics approvals.
Whether the trial is officially registered and provides proper informed-consent documents.
Whether the treating doctor and clinical establishment are appropriately registered.
Whether the clinic is making unsupported claims of guaranteed improvement or cure.
Whether the risks, possible benefits, alternatives and experimental status have been clearly explained.
The advisory’s central message is that stem cell science may hold research potential, but unproven interventions must not be sold as established treatment. Patients should rely on approved medical care and independently verify regulatory claims before making decisions.
Health Ministry issues stem cell therapy advisory
The Union Ministry of Health and Family Welfare has issued an advisory directing all states and Union Territories to strictly enforce the rules governing stem cell research and therapy. The advisory, dated September 16, 2026, asks healthcare establishments, medical professionals and regulatory authorities to prevent unapproved stem cell interventions from being offered as established treatments.
The Ministry has clarified that stem cell therapy can be used as routine clinical care only for diseases and indications included in its approved list. Any treatment outside those approved uses must be regarded as experimental and cannot be promoted as a standard or commercially proven medical service.
Key points:
Only stem cell therapies approved by the Health Ministry may be offered as routine clinical care.
Experimental stem cell interventions cannot be advertised or promoted as proven cures.
Hospitals, clinics and doctors must comply with the applicable research and treatment regulations.
State and district authorities have been directed to monitor clinical establishments and investigate reported violations.
Stem cell therapy for autism remains experimental
The advisory specifically addresses claims that stem cell therapy can treat Autism Spectrum Disorder. The government has made it clear that the therapeutic use of any type of stem cell for autism is not approved as routine or standard clinical treatment.
Stem cell interventions involving autism may be undertaken only as part of duly approved clinical trials. These studies must follow the National Guidelines for Stem Cell Research, 2017, jointly issued by the Indian Council of Medical Research and the Department of Biotechnology.
Important conditions include:
Stem cell therapy for autism must remain restricted to authorised clinical trials.
The clinical trial must receive all necessary regulatory and ethics approvals.
Clinics cannot market experimental autism interventions as routine medical services.
Doctors cannot claim that stem cells are an established cure for autism.
Parents and caregivers should confirm a trial’s official registration and approvals before considering participation.
The advisory does not prohibit legitimate research but requires it to be conducted under approved clinical-trial safeguards.
NMC warns doctors against unauthorised practices
The National Medical Commission has reinforced the regulatory position through its advisory dated September 5, 2026. It has warned registered medical practitioners against administering, prescribing, recommending, promoting or advertising stem cell therapies for unapproved indications.
The NMC has stated that involvement in unauthorised stem cell treatment could amount to professional misconduct. State Medical Councils have been advised to examine complaints and initiate disciplinary proceedings when violations are established after due process.
The NMC directions cover the following actions:
Administering stem cell therapy for an indication that has not been approved.
Prescribing an experimental intervention as standard treatment.
Promoting unproven therapies through websites, social media or advertisements.
Making unsupported claims about guaranteed recovery or a permanent cure.
Commercially offering stem cell therapy outside an authorised clinical trial.
Failing to properly explain the experimental status and potential risks to patients.
Supreme Court judgment prompted stronger enforcement
The Health Ministry’s advisory follows the Supreme Court’s January 30, 2026 judgment in Yash Charitable Trust and Others versus Union of India and Others. The ruling emphasised that failure to comply with the statutory framework governing stem cell therapy must result in appropriate consequences.
The advisory reminds authorities that the existence of scientific research into stem cells does not permit clinics to sell unapproved interventions. Every therapeutic use must comply with the approved framework, and experimental research must remain within regulated clinical trials.
The judgment and subsequent advisory underline that:
Unapproved stem cell interventions cannot be treated as ordinary medical services.
Regulatory violations must result in meaningful action.
Medical professionals can be investigated for professional misconduct.
Clinical establishments may face penalties or loss of registration.
State authorities are responsible for enforcing the rules at the local level.
Penalties for violating stem cell therapy rules
Doctors found responsible for unauthorised stem cell therapy may face professional-misconduct proceedings under Regulation 7.22 of the Indian Medical Council Regulations, 2002. Any disciplinary action must be taken after examining the evidence and following the required legal process.
Clinical establishments may separately face action under Sections 32 and 40 of the Clinical Establishments Registration and Regulation Act, 2010. Depending on the nature of the violation, this can include financial penalties and cancellation of registration.
Possible consequences include:
Professional-misconduct proceedings against registered medical practitioners.
Disciplinary action by State Medical Councils.
Investigation of hospitals and clinics offering unauthorised treatments.
Penalties under the Clinical Establishments Act.
Cancellation of a clinical establishment’s registration in applicable cases.
Action against misleading promotion or advertisement of unproven therapies.
What patients and families should verify
Patients should not assume that every treatment described as “stem cell therapy” is approved, safe or clinically effective. Before agreeing to any such intervention, they should consult a qualified specialist and verify whether the proposed treatment is authorised for their medical condition.
Patients and families should check:
Whether the proposed stem cell treatment is approved for the diagnosed condition.
Whether it is being offered as standard treatment or as part of a clinical trial.
Whether the clinical trial has valid regulatory and ethics approvals.
Whether the trial is officially registered and provides proper informed-consent documents.
Whether the treating doctor and clinical establishment are appropriately registered.
Whether the clinic is making unsupported claims of guaranteed improvement or cure.
Whether the risks, possible benefits, alternatives and experimental status have been clearly explained.
The advisory’s central message is that stem cell science may hold research potential, but unproven interventions must not be sold as established treatment. Patients should rely on approved medical care and independently verify regulatory claims before making decisions.
Supriya Yarlagadda has been appointed to the newly reconstituted Central Board of Film Certification, becoming one of its 18 members and providing Telugu cinema with representation on the national film-certification body.
Supriya Yarlagadda Joins Reconstituted CBFC
Supriya Yarlagadda has been named as one of the 18 members of the newly reconstituted Central Board of Film Certification
Supriya Yarlagadda has been appointed to the newly reconstituted Central Board of Film Certification, becoming one of its 18 members and providing Telugu cinema with representation on the national film-certification body.
Supriya Yarlagadda Joins Reconstituted CBFC
Supriya Yarlagadda has been named as one of the 18 members of the newly reconstituted Central Board of Film Certification
